drugset / Trial / NCT03965546
ET 140202 -T Cell Combined With TAE or Sorafenib in the Treatment of Liver Cancer
Phase 0
Unknown
27 enrolled
First Affiliated Hospital Xi'an Jiaotong University
Eureka Therapeutics Inc. · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the efficacy and safety of ET 140202 -T cell combined With TAE or Sorafenib in the treatment of liver cancer
Timeline
- Start
- 2019-05-30
- Primary completion
- 2021-06
- Completion
- 2022-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ET140202-T cell | Cell therapy | — | Intravenous |
| Subject | Sorafenib | Small molecule | 400 mg | — |